Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIVAP: Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia
NCT06834971Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of colistimethate sodium in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Incidence of a first VAP episode at 28 days. Started Jul 2025; status: recruiting.
02
Drugs
colistimethate sodium
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT06834971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834971.